Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder

Cannabis Use Clinical Trial

Official title: Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents

Status Recruiting

Clinical Trial Summary

This project seeks to learn more about the effects of cannabis use on the endocannabinoid system and endogenous opioid systems in adolescents to address a fundamental gap in knowledge and identify biomarkers that may help distinguish youth who relapse from youth who remain sober.

Clinical Trial Description

Learning the effects of cannabis use on the endocannabinoid system and endogenous opioid systems in adolescents addresses a fundamental gap in knowledge and may identify biomarkers that help distinguish youth who relapse from youth who remain sober.

The specific aims of the project are to:

1. Measure endocannabinoid (eCB) and endogenous opioid (endorphin) levels in the blood of adolescents who use cannabis regularly and adolescents who never use cannabis. We expect eCB and endorphin levels to differ significantly in adolescents who use cannabis regularly compared to adolescents who do not.

2. Characterize circulating eCB and endorphin levels at baseline, during abstinence, and after natural resumption of cannabis use.

3. Collect data to evaluate cannabis craving and to test for association of craving with eCB and endorphin levels in adolescents who use cannabis regularly. We expect that larger changes in eCB and endorphin levels will be associated with higher craving scores. ;

Related Conditions & MeSH terms

• Cannabis Use
• Marijuana Abuse

• NCT number: NCT05396638
• Study type: Interventional
• Source: University of Colorado, Denver
• Contact: Jesse Hinckley, MD, PhD
• Phone: 303-724-3090
• Email: jesse.hinckley@cuanschutz.edu
• Status: Recruiting
• Phase: N/A
• Start date: October 13, 2022
• Completion date: June 2024